Example: biology
Paxlovid Product Information
HMG-CoA reductase inhibitors . simvastatin Nonsteroidal anti-inflammatory drugs (NSAIDs) piroxicam Opioid analgesic pethidine PDE5 inhibitor avanafil, sildenafil, vardenafil, tadalafil Sedative/hypnotics diazepam . PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Guideline for the labelling of medicines
www.tga.gov.auGuideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014
Australian public assessment report for Linagliptin
www.tga.gov.au• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.
Australian Public Assessment Report for Silodosin
www.tga.gov.auAustralian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...
Guidance 18: Impurities in drug substances and …
www.tga.gov.auTherapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date
Explanatory notes for pharmaceutical manufacturers on the ...
www.tga.gov.auPE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …
The use of GMDN codes for IVD medical devices in Australia
www.tga.gov.auGlobal Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to
COMIRNATY™ COVID-19 VACCINE
www.tga.gov.auDo not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au
COVID-19 rapid antigen self-tests
www.tga.gov.auCOVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.
AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …
www.tga.gov.auAUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …
Australian public assessment report for BNT162b2 (mRNA)
www.tga.gov.auThe RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION o For patients …
docs.boehringer-ingelheim.com5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure 5.6 Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Reduction of Risk of Stroke and Systemic Embolism in Non- ...
Prophylaxis of DVT following hip or knee replacement …
packageinserts.bms.com7.1 Combined P-gp and Strong CYP3A4 Inhibitors 7.2 Combined P-gp and Strong CYP3A4 Inducers 7.3 Anticoagulants and Antiplatelet Agents 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment 10 OVERDOSAGE 11 …
HIGHLIGHTS OF PRESCRIBING INFORMATION Use of …
www.rxabbvie.com7.1 Strong CYP3A4 Inhibitors 7.2 Strong CYP3A4 Inducers 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment 11DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 …
Lynparza Full Prescribing Information
den8dhaj6zs0e.cloudfront.netCYP3A Inhibitors 2.5 Dosage Modifications for Renal Impairment 3 DOSAGE FORMS AND STRENGTHS. 4 CONTRAINDICATIONS. 5 WARNINGS AND PRECAUTIONS. 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia 5.2 Pneumonitis 5.3 Embryo-Fetal Toxicity 5.4 Venous Thromboembolic Events 6 ADVERSE REACTIONS. 6.1 Clinical Trial Experience …